Abstract
Herein, we report a case of bilateral simultaneous central retinal vein occlusion (CRVO) secondary to coronavirus disease 2019 (COVID-19). A 48-year-old man, with hypertension, type 2 diabetes mellitus, and stage 4 chronic kidney disease, diagnosed with COVID-19 1 month ago presented to the ophthalmology department with blurred vision in both eyes for 2 weeks. Ocular examination revealed a classic clinical presentation of CRVO in both eyes. Optical coherence tomography revealed increased central macular thickness with intraretinal and subretinal fluid in both eyes. Laboratory data revealed elevated D-dimer and C-reactive protein (CRP) levels. The levels of other hypercoagulability markers were normal. The patient received intravitreal anti-vascular endothelial growth factor therapy in both eyes, followed by regular follow-up every month until complete resolution of symptoms and gradual improvement of the retinal vascular appearance. COVID-19 can cause a variety of coagulation abnormalities and thromboembolic complications such as bilateral simultaneous CRVO. Clinicians and patients should be aware of ocular symptoms and presentations that are probably associated with COVID-19.
© 2023 The Author(s). Published by S. Karger AG, Basel
References
Harapan H, Itoh N, Yufika A, Winardi W, Keam S, Te H, et al. Coronavirus disease 2019 (COVID-19): a literature review. J Infect Public Health. 2020 May;13(5):667–73.
Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020 Feb;395(10223):497–506.
Wong RLM, Ting DSW, Wan KH, Lai KHW, Ko CN, Ruamviboonsuk P, et al. COVID-19: ocular manifestations and the APAO prevention guidelines for ophthalmic practices. Asia Pac J Ophthalmol. 2020 Jul–Aug;9(4):281–4.
Klein R, Moss SE, Meuer SM, Klein BEK. The 15-year cumulative incidence of retinal vein occlusion: the Beaver Dam Eye Study. Arch Ophthalmol. 2008;126(4):513–8.
Chen TY, Uppuluri A, Zarbin MA, Bhagat N. Risk factors for central retinal vein occlusion in young adults. Eur J Ophthalmol. 2021 Sep;31(5):2546–55.
Connors JM, Levy JH. COVID-19 and its implications for thrombosis and anticoagulation. Blood. 2020;135(23):2033–40.
Rehak M, Wiedemann P. Retinal vein thrombosis: pathogenesis and management. J Thromb Haemost. 2010;8(9):1886–94.
Merrill JT, Erkan D, Winakur J, James JA. Emerging evidence of a COVID-19 thrombotic syndrome has treatment implications. Nat Rev Rheumatol. 2020;16(10):581–9.
Oxley TJ, Mocco J, Majidi S, Kellner CP, Shoirah H, Singh IP, et al. Large-vessel stroke as a presenting feature of COVID-19 in the young. N Engl J Med. 2020 May;382(20):e60.
Szkodny D, Wylęgała E, Sujka-Franczak P, Chlasta-Twardzik E, Fiolka R, Tomczyk T, et al. Retinal OCT findings in patients after COVID infection. J Clin Med. 2021 Jul 22;10(15):3233.
Burgos-Blasco B, Güemes-Villahoz N, Vidal-Villegas B, Martinez-de-la-Casa JM, Donate-Lopez J, Martín-Sánchez FJ, et al. Optic nerve and macular optical coherence tomography in recovered COVID-19 patients. Eur J Ophthalmol. 2022 Jan;32(1):628–36.
Ullah I, Sohail A, Shah MUFA, Khurshid M, Diwan MN, Qadir A, et al. Central retinal vein occlusion in patients with COVID-19 infection: a systematic review. Ann Med Surg. 2021 Nov;71:102898.
Malakar M, Bhanot K, Farooqui NZ. Bilateral simultaneous central retinal vein occlusion with no other systemic association: case report. Austin J Clin Ophthalmol. 2019;6(1):1104.
Gaba WH, Ahmed D, Al Nuaimi RK, Dhanhani AA, Eatamadi H. Bilateral central retinal vein occlusion in a 40-year-old man with severe coronavirus disease 2019 (COVID-19) pneumonia. Am J Case Rep. 2020 Oct 29;21:e927691.
Khonsari N, Hasani H, Hakak-Zargar B, Poor Nami S. Bilateral central retinal vein occlusion and Stevens-Johnson syndrome associated with coronavirus-19: a case report. J Curr Ophthalmol. 2022 Apr 16;34(1):121–3.
Author Contacts
I-Ting Sun, whiterebecca912@gmail.com
Article / Publication Details
Received: November 09, 2022
Accepted: January 17, 2023
Published online: February 17, 2023
Issue release date: January – December
Number of Print Pages: 6
Number of Figures: 3
Number of Tables: 0
eISSN: 1663-2699 (Online)
For additional information: https://www.karger.com/COP
Open Access License / Drug Dosage / Disclaimer
This article is licensed under the Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC). Usage and distribution for commercial purposes requires written permission. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
留言 (0)